In a new survey of European and North American companies Mettler Toledo PCE has revealed the importance of serialisation in the fight against counterfeiting.
Biosimilars are increasing in popularity with pharma companies, however, an important consideration for the interested parties is knowing which markets are saturated and which are still open, according to data and analytic company, GlobalData.
In this online exclusive, Dr Karen Whiting, global head of New Product Development at BBI Solutions, looks at the evolution of the diagnostics market and how new approaches can help companies’ future-proof their products.
As the guidelines for the negotiations of future relations between the EU and the UK are approved, allowing the progression of Brexit talks, pharma, biotech and manufacturing industry leaders give their opinions on the transition.
Growth of $23 billion by the year 2021 is anticipated in the global cholesterol-lowering drugs market, according to a new report from business intelligence provider, Visiongain.
New research from Oracle Health Services in partnership with Informa Engage/Pharma Intelligence has revealed that more than 60% of drug safety experts are planning to use artificial intelligence (AI) to improve the speed and security
This year will be big for Duchenne muscular dystrophy (DMD) as interest in treatments is on the rise and deal activity is increasing, reported data and analytics company, GlobalData.
The ‘Amazon Effect’, new address systems and Brexit are driving change, in this online opinion article, BluJay Solutions presents the three most important trends to prepare for in 2018.
According to data and analytics company, GlobalData, new real-world evidence will support the use of a biosimilar treatment for Crohn’s disease (CD), leading to a boost in the biosimilar market value.
In our next instalment of ‘Meet the maker’, the new VP of Europe for The ACG Group, Steven Facer, discusses his past, present and visions of what future holds for pharma.
According to new research from global professional services company, Accenture, there is an estimated £22 billion that could be unlocked by pharmaceutical companies over the next 10 years through harnessing digital technologies.
